Search all trials

Find therapies in clinical trials near you – page 60

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 968
countries: 28
conditions: 2 103

3 968 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Cystic fibrosis

Not recruiting

Registered drugNo placebo

Study on Long-term Safety of VX-121, Tezacaftor, and Deutivacaftor in Patients with Cystic Fibrosis

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Deutivacaftor

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drugNo placebo

Study Comparing Sacituzumab Govitecan and Docetaxel for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Docetaxel

Contact Research Centre

Atypical haemolytic uraemic syndrome

Not recruiting

InvestigationalNo placebo

Study on the Effectiveness and Safety of Iptacopan for Adults with Atypical Hemolytic Uremic Syndrome Not Previously Treated with Complement Inhibitors

InvestigationalNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Iptacopan

Contact Research Centre

Small cell lung cancer

Not recruiting

Registered drugNo placebo

Study of Lurbinectedin Alone or with Irinotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Irinotecan

Contact Research Centre

Acute lymphocytic leukaemia

Not recruiting

Registered drugNo placebo

Study on Improving Treatment for Children and Adolescents with Acute Lymphoblastic Leukemia Using Bortezomib, Blinatumomab, and a Drug Combination

Registered drugNo placebo

Austria

Participants:0–17 years
Substances:Blinatumomab

Contact Research Centre

Multiple sclerosis

Not recruiting

Registered drugNo placebo

Study on Long-Term Safety and Efficacy of Ocrelizumab for Patients with Multiple Sclerosis

Registered drugNo placebo

Austria

Participants:18–64 years
Substances:Ocrelizumab

Contact Research Centre

Multiple sclerosis

Not recruiting

Registered drug

Study on the Effectiveness and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Children with Multiple Sclerosis

Registered drug

Austria

Participants:0–17 years
Substances:Ofatumumab

Contact Research Centre

Malignant melanoma stage III

Not recruiting

Registered drug

Study on Pembrolizumab for Patients with High-Risk Stage III Melanoma After Surgery

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Pembrolizumab

Contact Research Centre

Non-small cell lung cancer stage III

Not recruiting

Registered drugNo placebo

Study of Atezolizumab and Tiragolumab Compared to Durvalumab for Patients with Advanced Non-Small Cell Lung Cancer After Chemoradiation

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Atezolizumab

Contact Research Centre

Major depression

Not recruiting

Registered drugNo placebo

Study on Esketamine and Propofol for Anesthesia in Electroconvulsive Therapy for Patients with Major Depression

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Methohexital Sodium

Contact Research Centre

Deafness neurosensory

Not recruiting

Registered drug

Study on the Effectiveness and Safety of AC102 Injection vs. Oral Prednisolone for Patients with Sudden Hearing Loss

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Prednisolone

Contact Research Centre

HER2 mutant non-small cell lung cancer

Not recruiting

Registered drugNo placebo

Study on Trastuzumab Deruxtecan for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Find therapies in clinical trials near you – page 60

838 trials match your criteria

Cystic fibrosis

Study on Long-term Safety of VX-121, Tezacaftor, and Deutivacaftor in Patients with Cystic Fibrosis

Non-small cell lung cancer

Study Comparing Sacituzumab Govitecan and Docetaxel for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Atypical haemolytic uraemic syndrome

Study on the Effectiveness and Safety of Iptacopan for Adults with Atypical Hemolytic Uremic Syndrome Not Previously Treated with Complement Inhibitors

Small cell lung cancer

Study of Lurbinectedin Alone or with Irinotecan for Patients with Relapsed Small Cell Lung Cancer

Acute lymphocytic leukaemia

Study on Improving Treatment for Children and Adolescents with Acute Lymphoblastic Leukemia Using Bortezomib, Blinatumomab, and a Drug Combination

Multiple sclerosis

Study on Long-Term Safety and Efficacy of Ocrelizumab for Patients with Multiple Sclerosis

Multiple sclerosis

Study on the Effectiveness and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Children with Multiple Sclerosis

Malignant melanoma stage III

Study on Pembrolizumab for Patients with High-Risk Stage III Melanoma After Surgery

Non-small cell lung cancer stage III

Study of Atezolizumab and Tiragolumab Compared to Durvalumab for Patients with Advanced Non-Small Cell Lung Cancer After Chemoradiation

Major depression

Study on Esketamine and Propofol for Anesthesia in Electroconvulsive Therapy for Patients with Major Depression

Deafness neurosensory

Study on the Effectiveness and Safety of AC102 Injection vs. Oral Prednisolone for Patients with Sudden Hearing Loss

HER2 mutant non-small cell lung cancer

Study on Trastuzumab Deruxtecan for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.